Esophagogastric Junction Adenocarcinoma research hub
8 indexed studies · 5 currently recruiting
- recruitingPHASE1
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
This study is testing a new combination treatment for stomach or gullet cancer that can be removed with surgery. It combines a drug called Tislelizumab with standard chemotherapy (FLOT) given before the operation. We want to see if this new approach is safe and works well.
Germany - active not recruiting
Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany
This study in Germany looks at how stomach cancer care, treatments, and outcomes might be different for men and women. Researchers will check patient records to see if gender affects things like survival and how well treatments work, aiming to improve care for everyone.
Germany - not yet recruitingNA
Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer
This study looks at how well people with certain cancers stick to a special exercise program after chemotherapy. It uses smartwatches to track activity and checks if exercise helps reduce tiredness three months later.
France - active not recruitingPHASE2
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
This study looks at new drug combinations (Durvalumab and Tremelimumab with FOLFIRI chemotherapy) for advanced stomach or food pipe cancer that has already been treated. It aims to see how well patients respond and if these combinations can help people live longer.
France - recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
This study looks at a new blood test to find cancer early in people who have already been treated for certain cancers. It aims to see if this test can tell when cancer might come back, helping doctors give the best care sooner.
United States · France · Germany - recruiting
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
This study looks at oesophageal and stomach cancer patients after surgery. We're collecting samples over time to find early signs (biomarkers) that can predict how well treatments work, if the cancer might come back, or long-term health outcomes. The goal is to improve understanding and care for these cancers.
United Kingdom - active not recruitingPHASE2, PHASE3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.
United States · Australia · Belgium - not yet recruiting
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
This study is developing a simple breath test to help find common gut cancers earlier, like those in the food pipe, stomach, pancreas, liver, and bowel. Finding cancer early means better treatment options. We're testing if breathing into a special device can quickly spot these cancers by detecting tiny molecules in your breath.
United Kingdom